M
Martin S. Tallman
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 948
Citations - 71451
Martin S. Tallman is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 117, co-authored 917 publications receiving 60011 citations. Previous affiliations of Martin S. Tallman include University of Rome Tor Vergata & University of Toronto.
Papers
More filters
Journal ArticleDOI
Breakthrough zygomycoses in patients receiving antifungal therapy with voriconazole
TL;DR: This retrospectively analyzed the clinical records of 109 patients at Robert H Luire Comprehensive Cancer Center who were on Voriconazole for prophylaxis, empiric or pathology proven therapy during a period of May 2003 till December 2004 to find four patients had proven infection with invasive zygomycosis.
Journal Article
Phase II trial of darinaparsin (ZIO-101) in leukemias and lymphomas
TL;DR: Darinaparsin is active against diverse cancers in vitro and in animal models of leukemia and lymphoma, and has a multifunctional mechanism of action that is mediated by disrupted mitochondrial function, increased reactive oxygen species (ROS) production, modified signal transduction, and antiangiogenesis.
Journal ArticleDOI
Targeted detection and quantitation of histone modifications from 1,000 cells
Nebiyu Abshiru,Jacek Sikora,Jeannie M. Camarillo,Juliette A. Morris,Philip D. Compton,Tak C. Lee,Yaseswini Neelamraju,Samuel Haddox,Caroline Sheridan,Martin Carroll,Larry D. Cripe,Martin S. Tallman,Elisabeth Paietta,Ari Melnick,Paul M. Thomas,Francine E. Garrett-Bakelman,Francine E. Garrett-Bakelman,Neil L. Kelleher +17 more
TL;DR: A quantitative LC-MS/MS approach tailored for a targeted histone assay of 75 hist one peptides with as few as 10,000 cells was developed and validated and was able to detect and quantify 61 histone peptides from just 1,000 primary human stem cells.
Journal ArticleDOI
Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status
Alessandra Cesano,Santosh Putta,Kavita Mathi,David B. Rosen,Urte Gayko,Rachael E. Hawtin,Larry D. Cripe,Zhuoxin Sun,Martin S. Tallman,Elisabeth Paietta +9 more
TL;DR: It is confirmed that levels of FLT3 ligand (FLT3L)-induced signaling (as measured by changes in intracellular phospho-S6 level) are more homogeneous in FlT3 ITD+ than in FLT2 ITD- myeloblasts, and that variance is decreased with increasing mutational load.
Journal ArticleDOI
Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
John F. DiPersio,Harry P. Erba,Richard A. Larson,Selina M. Luger,Mangan Kf,Martin S. Tallman,Jeffrey Mark Brill,Gregoire Vuagniaux,Elisabeth Rouits,Claudio Zanna,J. Mel Sorensen +10 more
TL;DR: Treatment of AML remains difficult due to the development of treatment resistance, and inhibitors of apoptosis proteins (IAPs) are key negative modulators of apoptotic death which represent a major source of resistance.